Ambroxol, who has tried it?

[Ambroxol-Curious]

Hi all,

It seems there are trials on this existing drug, used as a cough medicine, to establish if it can be repurposed as an effective PD drug.

I'm interested to hear from people who have tried this/ are trying this and to hear your experiences.

Many thanks,

Tony

[limcheeese22]

Yes, tried for one year with full dose, no effect on me.

[Doblady in reply to limcheeese22]

my husband has parkinism with lewey body and has been taking Ambroxol 75 g apsules twice a day for 12months his cognitive response improved and since dose has doubled he has improved imensly

[CuriousMe12 in reply to Doblady]

Hi Doblady Can I ask what brand and where you sourced your product from ?

[acceptanceand in reply to Doblady]

Hi Doblady, that is fantastic news. What symptoms do you think might have improved since starting with Ambroxol in addition to his cognition?

[M-o-ggy in reply to Doblady]

Would you be willing to share the brand you use ?

[Journey4Health]

I ordered it but haven’t tried yet.

[LiesBram]

Im on it at the moment the max dose according to the trials phase 1, the safe doses is 1,2g/day

However the are I believe trials going on in phase 2 were the are up to 1,8g/day I am even up to 2,0g/d and no side effects.

I have no clear respons yet however I got the feeling that now after 4 months the my cognitive response improved I will at least take it for one year maybe (if no side effects) even longer

Im producing my own capsules and getting my ambroxol from India

[acceptanceand in reply to LiesBram]

Thank you for your response Lies Bram.

Did you say you are taking 2 g per day now?

Are you part of the trial or did you just decide yourself to try Ambroxol?

Tony

[LiesBram in reply to acceptanceand]

yes I am on 2g/day No Im not part part of a trial

[acceptanceand in reply to LiesBram]

Thanks, what prompted you / persuaded you to try it?

[LiesBram in reply to acceptanceand]

this Forum

[PEPSY2020]

STATUT

Complété

LES CONDITIONS

Maladie de Parkinson

INTERVENTION / TRAITEMENT

Médicament: Ambroxol

DESCRIPTION DÉTAILLÉE

L'étude AiM-PD recrutera 20 patients (10 GBA-positifs et 10 GBA-négatifs) diagnostiqués avec la maladie de Parkinson (MP). Chaque patient s'auto-administrera le médicament à l'étude, l'ambroxol (60 mg par comprimé) à 5 augmentations de doses intra-dosées sur une période de 6 mois, comme indiqué ci-dessous :

Jour 1 à 7 : 60 mg trois fois par jour

Jour 8-14 : 120 mg trois fois par jour

Jour 15-21 : 180 mg trois fois par jour

Jour 22-28 : 300 mg trois fois par jour

Jour 29-186 : 420 mg trois fois par jour

Le médicament à l'étude est autorisé dans l'UE en tant que médicament en vente libre pour traiter les affections respiratoires en réduisant la production de mucus. Des études antérieures ont montré que l'ambroxol peut pénétrer dans le cerveau chez des modèles de rongeurs et de primates non humains, et peut avoir un effet sur le ralentissement de la MP. Les résultats indiquent également que les individus qui expriment la mutation GBA (risque accru de MP) sont capables de réduire la croissance des cellules qui causent la MP en stimulant une enzyme appelée glucocérébrosidase.

L'étude recueillera des échantillons de liquide céphalo-rachidien, de sang et d'urine avant, pendant et après la prise du médicament sur une période de 6 mois. Dans ces échantillons, les enquêteurs mesureront les niveaux de médicament ambroxol, évalueront si l'enzyme glucocérébrosidase a été stimulée et les niveaux d'autres substances supposées être associées au développement de la MP et confirmeront si le médicament à l'étude a pénétré dans le liquide céphalo-rachidien et le SNC. L'étude administrera des évaluations cliniques et cognitives pour déterminer s'il y a une amélioration des symptômes de la MP du patient. Si l'étude prouve que l'ambroxol pénètre dans le SNC et reproduit nos découvertes actuelles en laboratoire, les enquêteurs passeront à un essai de médicament beaucoup plus vaste pour tester si le médicament à l'étude peut ralentir la progression de la MP.

TYPE D'ÉTUDE

Interventionnel

INSCRIPTION (RÉEL)

23

PHASE

Phase 2

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

Royaume-Uni

London, Royaume-Uni

Leonard Wolfson Experimental Neurology Centre Clinical Research Facility

[Berylhorsey1]

there is a trial going on at Kings College Hospital in London I believe.

[ZebraDoodle in reply to Berylhorsey1]

Hi, do you mean this? Their recent newsletter (June 24) said:

"We are very excited for the launch of the phase III clinical trial ASPro-PD, which will investigate the repurposed cough medication Ambroxol. This study aims to assess the efficacy of ambroxol in slowing down the progression of PD and will be recruiting from a selection of participants with PD that have both the ‘normal’ wildtype GBA1 gene and the mutated GBA1 gene.

Due to delays with reformulating the drug, our previous issue announced that the start date of ASPro-PD would be pushed back. We are thrilled to share that the drug reformulation has been completed. Following this progress with drug development, the ASPro-PD Clinical Trial Unit, with help from the Cure Parkinson’s team and PD Frontline team, have been working hard to get all the necessary arrangements in place ready for recruitment to begin - which we now expect to be in the Autumn.

PD Frontline will be identifying participants that meet preliminary eligibility criteria based on age, disease duration and genetic results. These participants will be referred for a screening visit at a local NHS trial site, where full eligibility will be discussed and any questions about the trial can be answered. PD Frontline will be reaching out to potential participants in the weeks coming up to the start of the trial.

There are 15 potential research centres delivering the ASPro-PD study across the UK, with a target of 330 participants to be recruited over a period of two years.

...

Eligibility

GBA1 carrier / non-carrier

35- 75 y e a r s old

PD diagnosis within the last 7 years

No history of DBS

Further criteria"

Their website is:

pdfrontline.com/en